Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /COVID-19 /Inovio Pharmaceuticals boosts Covid-19 vaccine manufacturing

Inovio Pharmaceuticals boosts Covid-19 vaccine manufacturing

by JMC on May 1, 2020

Inovio Pharmaceuticals has signed an agreement with German contract manufacturer Richter-Helm BioLogics for large-scale production of Covid-19 DNA vaccine candidate, INO-4800.

The deal, partially funded by a $1.3m initial grant from the Coalition for Epidemic Preparedness Innovations (CEPI), includes a total of $17.2m support for INO-4800 development.

Richter-Helm BioLogics has been manufacturing Inovio’s other DNA drug candidate VGX-3100 has been in manufacture since 2014, which is currently in Phase III clinical trials to treat precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV).

Inovio commercial-scale plasmid manufacturing at Richter-Helm BioLogics for its DNA medicines platform.

The aim is to manufacture one million INO-4800 doses by the end of this year.

Any additional capacity offered by Richter-Helm could significantly boost manufacturing of the Covid-19 vaccine candidate to meet urgent needs during the pandemic.

Richter-Helm BioLogics managing director Dr Kai Pohlmeyer said: “We will mobilise all our resources to ensure sufficient supply of late-stage clinical and commercial batches of INO-4800 and contribute to the fight against the deadly Covid-19 pandemic.”

Source: Inovio Pharmaceuticals boosts Covid-19 vaccine manufacturing

Previous post:

Next post: